Video

Dr. Deol on the FDA Approval of Eltrombopag in Severe Aplastic Anemia

Author(s):

Abhinav Deol, MD

Abhinav Deol, MD, associate professor, Karmanos Cancer Institute, discusses the expanded FDA approval of eltrombopag (Promacta) in combination with standard immunosuppressive therapy for the treatment of newly diagnosed adult and pediatric patients 2 years and older with severe aplastic anemia.

Abhinav Deol, MD, associate professor, Karmanos Cancer Institute, discusses the expanded FDA approval of eltrombopag (Promacta) in combination with standard immunosuppressive therapy for the treatment of newly diagnosed adult and pediatric patients 2 years and older with severe aplastic anemia.

Related Videos
J. Bradley Elder, MD
Rimas V. Lukas, MD
Shubham Pant, MD, MBBS
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Related Content
Jorge E. Cortes, MD, of Georgia Cancer Center
November 21st 2024

An Era of Firsts in CML: Asciminib Challenges SOC TKIs

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Acute Myeloid Leukemia
November 15th 2024

Venetoclax Plus 10-Day Decitabine Produces Responses in High-Risk MDS, AML

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Alex F. Herrera, MD
November 14th 2024

Data for Nivolumab Plus AVD Could Help Harmonize Treatment of Older and Younger Advanced-Stage Hodgkin Lymphoma

Jennifer Amengual, MD, Herbert Irving Assistant Professor of Medicine, Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center
November 13th 2024

Real-World Experience With CAR T Varies From Trials in DLBCL